Abstract
Background
Studies have shown that along with primary tumor response, lymph node status after RTx/CTx is one of the most important prognostic factors for advanced esophageal carcinoma. The goal of our study was to investigate the influence of neoadjuvant radiochemotherapy (RTx/CTx) on lymph nodes (LN).
Materials and Methods
From 1997 until 2006, 297 patients underwent surgery for advanced esophageal carcinoma. Of these, 192 received preoperative chemoradiation (5-FU, cisplatin, 36 Gy). The following matched subgroups were chosen: Group I, 20 with surgery alone: 10 adenocarcinoma (AC), 10 squamous cell carcinoma (SCC); Group II, 20 with minor response (10 AC, 10 SCC); Group III, 20 with major response (10 AC, 10 SCC). Tumor response was graded as “minor” or “major” according to the Cologne Regression Scale, the LN size determined by the largest measured diameter.
Results
A total of 1967 LNs from 60 patients were examined. Of these, 161 LNs showed metastasis. The median number of LNs examined per patient was not significantly higher in group I compared with the group with pretreatment (32 vs 31). Group I and group II showed LN metastasis (LNM) in 65% of cases, and group III in only 20% (p = 0.011). LNMs after pretreatment had significantly smaller median diameters (5.0 mm) than those without (7.0 mm) (p < 0.02). Nonmetastatic LN size did not vary between the three groups. LN size with and without metastasis did not differ between AC and SCC or between major and minor responders.
Conclusion
With good response to neoadjuvant radiochemotherapy, the size and the number of metastatic LNs is significantly reduced regardless of histologic cancer type.
Similar content being viewed by others
References
Stahl M, Walz M, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.
Tepper J, Krasna M, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.
Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, et al. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction—the impact of clinical heterogeneity. Am J Clin Oncol. 2007;30:172–80.
Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231–8.
Schneider P, Baldus S, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–92.
Mariette C, Piessen G, Briez N, Triboulet J. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.
Prenzel K, Konig A, Schneider P, Schnickmann C, Baldus SE, Schroder W, et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol. 2007;14:954–9.
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med. 1996;335:462–7.
Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J Surg. 2006;30:2182–90; discussion 2191–2.
Read T, Andujar J, Caushaj P, Johnston DR, Dietz DW, Myerson RJ, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum. 2004;47:825–31.
Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009;10:785–93.
Schröder W, Baldus S, Monig S, Beckurts T, Dienes H, Hölscher A. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg. 2002;26:584–7.
Sobin L, Wittekind C. UICC (2002) TNM Classification of Malignant Tumors. 6th ed. New York: Wiley & Sons, 2002.
Hölscher A, Schroder W, Bollschweiler E, Beckurts K, Schneider P. How safe is high intrathoracic esophagogastrostomy? Chirurg. 2003;74:726–33.
Baldus S, Monig S, Schroder W, Metzger R, Lang S, Zirbes TK, et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe. 2004;25:421–7.
Wichmann M, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg. 2002;137:206–10.
Maschuw K, Kress R, Ramaswamy A, Braun I, Langer P, Gerdes B. Short-term preoperative radiotherapy in rectal cancer patients leads to a reduction of the detectable number of lymph nodes in resection specimens. Langenbecks Arch Surg. 2006;391:364–8.
Taflampas P, Christodoulakis M, Gourtsoyianni S, Leventi K, Melissas J, Tsiftsis D. The effect of preoperative chemoradiotherapy on lymph node harvest after total mesorectal excision for rectal cancer. Dis Colon Rectum. 2009;52:1470–4.
Perez R, Pereira D, Proscurshim I, Gama-Rodrigues J, Rawet V, São Julião GP, Kiss D, Cecconello I, Habr-Gama A. et al. Lymph node size in rectal cancer following neoadjuvant chemoradiation—can we rely on radiologic nodal staging after chemoradiation? Dis Colon Rectum. 2009;52:1278–84.
Twine C, Lewis W, Morgan M, Chan D, Clark GW, Havard T, et al. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology. 2009;55:46–52.
Greenstein A, Litle V, Swanson S, Divino C, Packer S, Wisnivesky J. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.
Wilson M, Rosato E, Chojnacki K, Chervoneva I, Kairys JC, Cohn HE, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res. 2008;146:11–5.
Peyre C, Hagen J, De MS, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.
Altorki N, Zhou X, Stiles B, Port JL, Paul S, Lee PC, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.
Barbour A, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894–902.
Jamieson G, Thompson S. Detection of lymph node metastases in oesophageal cancer. Br J Surg. 2009;96:21–5.
Adelstein D, Rice T, Becker M, Larto MA, Kirby TJ, Koka A, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 1997;80:1011–20.
Schneider P, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902–8.
Leers J, Ayazi S, Hagen J, Terterov S, Klipfel N, Oezcelik A, et al. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status. J Am Coll Surg. 2009;208:553–6.
Metzger R, Drebber U, Baldus SE, Monig SP, Holscher AH, Bollschweiler E: Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus. Ann Surg Oncol. 2009;16:447–53.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bollschweiler, E., Besch, S., Drebber, U. et al. Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer. Ann Surg Oncol 17, 3187–3194 (2010). https://doi.org/10.1245/s10434-010-1196-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-010-1196-8